Global pharmaceutical giant Eli Lilly will invest a total of $500 million in South Korea over the next five years, the company announced Thursday.
The Ministry of Health and Welfare signed a memorandum of understanding with Eli Lilly at the Nine Tree Premier Rocaus Hotel in Yongsan-gu, Seoul, on Thursday afternoon for "the development of Korea's pharmaceutical and bio industry and the improvement of public health."
The investment follows similar commitments by AstraZeneca and Roche, signaling that major pharmaceutical companies are positioning Korea as a key hub for research and development in their innovation ecosystems.
The deal came after Eli Lilly approached the Korean government about large-scale investment opportunities following the government's announcement last September of its strategy to make Korea a "top five global power in the K-bio pharmaceutical industry."
Under the agreement, both parties will jointly pursue the establishment of "Lilly Gateway Labs" to nurture promising domestic biotech companies, expand recruitment of global-standard clinical trials, and conduct social contribution activities for underserved populations in healthcare.
The ministry and Eli Lilly plan to operate a joint working-level consultative body following the agreement to continue strengthening the domestic pharmaceutical and biotech innovation ecosystem and expanding global clinical trials.
Korea Becomes Asia's Second Gateway Labs Location
The Lilly Gateway Labs to be established in Korea is a shared innovation platform currently operating in six locations worldwide. Korea is expected to become the second location in Asia after China and the seventh globally.
Experts said global pharmaceutical companies, which had previously prioritized Singapore and Japan when establishing Asian bases, chose Korea as their top partner due to their high regard for the qualitative growth of Korea's clinical pipeline. Korea currently ranks third globally in clinical pipeline rankings, behind only the United States and China.
The core of this investment is transplanting Lilly's global open innovation model to Korea. Gateway Labs, already operating in major bio clusters such as San Francisco and Boston, goes beyond simply providing laboratory space to promising biotech companies. It is a "comprehensive incubating" approach that shares Lilly's R&D expertise and supports the entire process from preclinical to integrated clinical stages.
Platform Technologies Drive Big Pharma Interest
Behind this strategic move lies the unique platform technologies of Korean biotech companies. Technologies recognized as global standards—including Alteogen's Hybrozyme, LegoChem Biosciences' ConjuAll, and ABL Bio's Grabody-B—have proven the status of Korea's bio industry and served as decisive incentives for big pharma to select Korea as a key Asian hub.
Lilly is expected to pursue aggressive collaboration with domestic companies across its core R&D areas rather than limiting itself to specific fields. Obesity and diabetes (GLP-1), neurological diseases such as Alzheimer's, and immuno-oncology are expected to be key targets. Collaboration possibilities with companies possessing long-acting injectable technologies, such as Peptron and Inventage Lab, are already being discussed. Additional technology convergence models with ABL Bio, with which Lilly has already established a partnership in neurological diseases, are also anticipated.
AI Drug Development Strategy
Particularly notable is Lilly's artificial intelligence drug development strategy. Lilly has established an AI innovation lab jointly with AI semiconductor company Nvidia and operates its own machine learning platform called "Lilly TuneLab," making rapid discovery of drug candidates using AI a top priority. Given that Lilly is advancing its vast clinical data into sophisticated AI models, domestic AI drug development companies with technological capabilities are highly likely to move into Gateway Labs and utilize Lilly's infrastructure.
Patrick Johnson, President of Lilly International, said, "We hope this agreement will help Korea grow as a global leader in the pharmaceutical and bio industry and contribute to patient treatment and public health improvement, including better access to innovative medicines."
Wave of Big Pharma Investment
The trend of global big pharma heading to Korea is spreading across the industry. Roche recently confirmed a large-scale investment of approximately 710 billion won ($500 million) in Korea and has begun building a data-driven precision medicine ecosystem. AstraZeneca is also working closely with Korean researchers and focusing on discovering next-generation innovative technologies.
An official from a domestic pharmaceutical and biotech company said, "If the 'co-growth model' that has been validated in major countries such as the UK successfully takes root in Korea, it will serve as a catalyst for improving the structure of the domestic industry." The official added, "Korea is establishing itself as an essential base leading Asian innovation for global big pharma and as a hub for new drug development, going beyond simple contract manufacturing."
